Management Team

Mr. Vigdor is a business and corporate development specialist with extensive entrepreneurial and international experience ranging across industries and technologies. Prior to joining TCD Mr. Vigdor filled the positions of Business Development Director in CRB, and Strategic Alliance Director in BioCancell Therapeutics, a publicly traded biotechnology start up, where he was responsible for business and corporate development as well as investor and public relations. Mr. Vigdor holds a LL.B in Law and a B.A in Business Administration from the Hebrew University of Jerusalem, Israel and an MBA from the Instituto de Empresa, Madrid, Spain, where he has graduated first in his class.

With over 18 years of accumulative experience in biotech industry and research, Dr. Palacios is leading the development process in TCD. Prior to joining TCD, Dr. Palacios filled the positions of head of the clinical development department in the Chemo Group, Clinical Project Leader within the Medical Department of Almirall Laboratories (Barcelona, Spain) and a Senior Clinical Research Scientist at the headquarters of Novartis Pharma in Basel. Dr. Palacios experience ranges a wide variety of therapeutic areas from gynecology and respiratory to dermatology, allergy and cardiovascular. Her expertise covers the full scope of clinical development process starting at the design and implementation of clinical development programs to European and FDA submission. Before entering the pharmaceutical industry, Dr. Palacios spent some 7 years working on basic research at different laboratories. She completed her PhD degree with "Cum Laude" in 1994 in the Pharmacology Department of the University of Salamanca (Salamanca, Spain) and was a postdoctoral fellow at the Department of Pharmacology & Therapeutics, University of British Columbia (Vancouver, Canada) for 3 years. Beatriz is a pharmacist by training and holds a Postgraduate Diploma in Pharmaceutical Medicine from the Universities of Basel (Switzerland), Louis Pasteur, Strasbourg (France) and Albert-Ludwigs, Freiburg i.Br. (Germany).

Dr. Occleston has more than 22 years of research experience in the academic, biotech and pharmaceutical sectors. He has held a range of positions at University College London, Pfizer and Renovo (all UK) and is leading the Drug Discovery activities at TCD. Prior to joining TCD, Dr. Occleston filled the position of Senior Vice President of Discovery at Renovo, successfully building and leading a team of more than 30 scientists in a wide range of activities ranging from early target identification and validation through to the transition of approaches into early clinical studies, scientifically supporting approaches through the later phases of development and the identification and evaluation of new opportunities. Dr. Occleston has experience in supporting and helping drive the transitions of a small early spinout Company (Renovo; around 10 employees) through to IPO supporting structural growth to around 200 employees. He holds a BSc (Hons) from the University of Central Lancashire, UK, a M.Phil from the Manchester Metropolitan University and a PhD from the University of London (University College London), UK. He has over 35 scientific publications, is the co-inventor on over 25 patents and has presented widely at international Scientific Conferences.